NASDAQ:NVAX - Novavax Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.05 -0.05 (-2.38 %) (As of 01/21/2019 06:00 AM ET)Previous Close$2.05Today's Range$2.00 - $2.1252-Week Range$1.15 - $2.75Volume9.91 million shsAverage Volume9.53 million shsMarket Capitalization$784.84 millionP/E Ratio-3.25Dividend YieldN/ABeta2.19 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland. Receive NVAX News and Ratings via Email Sign-up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:NVAX Previous Symbol CUSIP67000210 Webwww.novavax.com Phone240-268-2000Debt Debt-to-Equity RatioN/A Current Ratio3.44 Quick Ratio3.44Price-To-Earnings Trailing P/E Ratio-3.25 Forward P/E Ratio-4.02 P/E GrowthN/A Sales & Book Value Annual Sales$31.18 million Price / Sales25.17 Cash FlowN/A Price / Cash FlowN/A Book Value($0.31) per share Price / Book-6.61Profitability EPS (Most Recent Fiscal Year)($0.63) Net Income$-183,760,000.00 Net Margins-482.87% Return on EquityN/A Return on Assets-66.83%Miscellaneous Employees347 Outstanding Shares382,850,000Market Cap$784.84 million OptionableOptionable Novavax (NASDAQ:NVAX) Frequently Asked Questions What is Novavax's stock symbol? Novavax trades on the NASDAQ under the ticker symbol "NVAX." How were Novavax's earnings last quarter? Novavax, Inc. (NASDAQ:NVAX) released its quarterly earnings data on Wednesday, November, 7th. The biopharmaceutical company reported ($0.12) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.12). The biopharmaceutical company earned $7.70 million during the quarter, compared to analyst estimates of $9.63 million. The firm's revenue was down 8.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.15) EPS. View Novavax's Earnings History. When is Novavax's next earnings date? Novavax is scheduled to release their next quarterly earnings announcement on Wednesday, March 13th 2019. View Earnings Estimates for Novavax. What price target have analysts set for NVAX? 10 brokers have issued 1 year target prices for Novavax's stock. Their forecasts range from $2.00 to $10.00. On average, they anticipate Novavax's stock price to reach $4.2778 in the next twelve months. This suggests a possible upside of 108.7% from the stock's current price. View Analyst Price Targets for Novavax. What is the consensus analysts' recommendation for Novavax? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novavax. Has Novavax been receiving favorable news coverage? Media headlines about NVAX stock have trended somewhat negative recently, InfoTrie reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novavax earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. Are investors shorting Novavax? Novavax saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 58,279,086 shares, an increase of 8.9% from the December 14th total of 53,500,990 shares. Based on an average daily trading volume, of 10,877,017 shares, the days-to-cover ratio is presently 5.4 days. Approximately 15.4% of the shares of the stock are short sold. View Novavax's Current Options Chain. Who are some of Novavax's key competitors? Some companies that are related to Novavax include China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Editas Medicine (EDIT), Autolus Therapeutics (AUTL), Momenta Pharmaceuticals (MNTA), Sangamo Therapeutics (SGMO) and Iovance Biotherapeutics (IOVA). Who are Novavax's key executives? Novavax's management team includes the folowing people: Mr. Stanley Charles Erck, Pres, CEO & Director (Age 71)Mr. John Joseph Trizzino, Sr. VP, Chief Bus. Officer, CFO & Treasurer (Age 59)Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 53)Dr. Gregory M. Glenn, Pres of R&D (Age 65)Mr. Sven Andréasson M.B.A., Sr. VP of Corp. Devel. (Age 67) Who are Novavax's major shareholders? Novavax's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.02%). Company insiders that own Novavax stock include Barclay A Phillips, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Institutional Ownership Trends for Novavax. Which institutional investors are buying Novavax stock? NVAX stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Novavax stock in the last two years include Barclay A Phillips, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Insider Buying and Selling for Novavax. How do I buy shares of Novavax? Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Novavax's stock price today? One share of NVAX stock can currently be purchased for approximately $2.05. How big of a company is Novavax? Novavax has a market capitalization of $784.84 million and generates $31.18 million in revenue each year. The biopharmaceutical company earns $-183,760,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Novavax employs 347 workers across the globe. What is Novavax's official website? The official website for Novavax is http://www.novavax.com. How can I contact Novavax? Novavax's mailing address is 20 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected] MarketBeat Community Rating for Novavax (NASDAQ NVAX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 455 (Vote Outperform)Underperform Votes: 330 (Vote Underperform)Total Votes: 785MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe NVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVAX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/21/2019 by MarketBeat.com StaffFeatured Article: What is an investor looking for in an SEC filing?